Designer benzodiazepine rat pharmacokinetics: A comparison of alprazolam, flualprazolam and flubromazolam

Designer benzodiazepines, including flualprazolam and flubromazolam, are clandestinely produced to circumvent federal regulations. Although flualprazolam and flubromazolam are structurally similar to alprazolam, they do not have an approved medical indication. Flualprazolam differs from alprazolam b...

Full description

Saved in:
Bibliographic Details
Published in:Toxicology and applied pharmacology 2023-04, Vol.465, p.116459-116459, Article 116459
Main Authors: Canfield, Jeremy R., Kisor, David F., Sprague, Jon E.
Format: Article
Language:English
Subjects:
Alprazolam
Alprazolam - pharmacokinetics
Alprazolam - toxicity
Animals
Benzodiazepines - pharmacokinetics
Benzodiazepines - toxicity
Designer Benzodiazepines
Designer Drugs - pharmacokinetics
Designer Drugs - toxicity
Flualprazolam
Flubromazolam
Fluorine
Male
Pharmacokinetics
Rats
Rats, Sprague-Dawley
Substance Abuse Detection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Designer benzodiazepines, including flualprazolam and flubromazolam, are clandestinely produced to circumvent federal regulations. Although flualprazolam and flubromazolam are structurally similar to alprazolam, they do not have an approved medical indication. Flualprazolam differs from alprazolam by the addition of a single fluorine atom. Whereas, flubromazolam differs by the addition of a single fluorine atom and substitution of a bromine for a chlorine atom. The pharmacokinetics of these designer compounds have not been extensively evaluated. In the present study, we evaluated flualprazolam and flubromazolam in a rat model and compared the pharmacokinetics of both compounds to alprazolam. Twelve male, Sprague-Dawley rats were given a 2 mg/kg subcutaneous dose of alprazolam, flualprazolam and flubromazolam and plasma pharmacokinetic parameters were evaluated. Both compounds displayed significant two-fold increases in volume of distribution and clearance. Additionally, flualprazolam displayed a significant increase in half-life leading to a nearly double half-life when compared to alprazolam. The findings of this study demonstrate that fluorination of the alprazolam pharmacophore increases pharmacokinetic parameters including half-life and volume of distribution. The increase in these parameters for flualprazolam and flubromazolam leads to an overall increased exposure in the body and a potential for greater toxicity than alprazolam. •Flualprazolam and flubromazolam are clandestinely produced designer benzodiazepines.•Designer benzodiazepines display altered pharmacokinetic parameters.•Halogenation led to an altered half-life, volume of distribution and clearance.
ISSN:0041-008X
1096-0333
DOI:10.1016/j.taap.2023.116459